---
title: "Qulipta (atogepant) in preventive treatment of migraine: Specific populations questions"
description: "Specific populations questions on Qulipta (atogepant) in preventive treatment of migraine, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Pregnancy and breastfeeding and Pediatric use. Questions: Is Qulipta safe during pregnancy? Can you take Qulipta while breastfeeding? Can children or teenagers take Qulipta? Is Qulipta safe for older adults (65 and over)? 2 further questions follow. 6 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/qulipta--preventive-treatment-of-migraine/specific-populations"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Qulipta (atogepant) in preventive treatment of migraine: Specific populations questions

Manufacturer: AbbVie Inc.  
Prescribing information: [Qulipta](https://www.rxabbvie.com/pdf/qulipta_pi.pdf)

## Pregnancy and breastfeeding

<a id="qulipta-pregnancy"></a>

### Is Qulipta safe during pregnancy?

> “There are no adequate data on the developmental risk associated with the use of QULIPTA in 
> pregnant women. In animal studies, oral administration of atogepant during the period of 
> organogenesis (rats and rabbits) or throughout pregnancy and lactation (rats) resulted in adverse 
> developmental effects (decreased fetal and offspring body weight in rats; increased incidence of 
> fetal structural variations in rabbits) at exposures greater than those used clinically [see Data].”

Source: [QULIPTA: Prescribing information, page 6, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=6)

> “There is a pregnancy exposure registry that monitors outcomes in women who become pregnant 
> while taking QULIPTA. Patients should be encouraged to enroll by calling 1-833-277-0206 or 
> visiting http://empresspregnancyregistry.com.”

Source: [QULIPTA: Prescribing information, page 6, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=6)

> “The effect of QULIPTA on pregnancy has not been clinically evaluated.<sup>1</sup>”

Source: [QULIPTA: QULIPTA® Once-Daily Dosing – QULIPTA® (atogepant) HCP, captured 2026-11-14](https://www.quliptahcp.com/qulipta-dosing#:~:text=The%20effect%20of%20QULIPTA%20on%20pregnancy%20has%20not%20been%20clinically)

<a id="qulipta-breastfeeding"></a>

### Can you take Qulipta while breastfeeding?

> “Data from a lactation study in twelve healthy adult females indicate that atogepant is excreted in 
> breast milk in low amounts. The estimated relative infant dose is approximately 0.19% of the 
> maternal weight-adjusted dose, and the milk-to-plasma ratio is 0.08 (see Data). There are no data 
> on the effects of atogepant on the breastfed infant or the effects on milk production. The 
> developmental and health benefits of breastfeeding should be considered along with the mother’s 
> clinical need for QULIPTA and any potential adverse effects on the breastfed infant from 
> QULIPTA or from the underlying maternal condition.”

Source: [QULIPTA: Prescribing information, page 7, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=7)

## Pediatric use

<a id="qulipta-pediatric"></a>

### Can children or teenagers take Qulipta?

> “Safety and effectiveness in pediatric patients have not been established.”

Source: [QULIPTA: Prescribing information, page 7, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=7)

## Specific populations

<a id="qulipta-geriatric"></a>

### Is Qulipta safe for older adults (65 and over)?

> “Population pharmacokinetic modeling suggests no clinically significant pharmacokinetic 
> differences between elderly and younger subjects. Clinical studies of QULIPTA did not include 
> sufficient numbers of patients aged 65 years and over to determine whether they respond 
> differently from younger patients. In general, dose selection for an elderly patient should be”

Source: [QULIPTA: Prescribing information, page 7, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=7)

> “cautious, usually starting at the low end of the dosing range reflecting the greater frequency of 
> decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.”

Source: [QULIPTA: Prescribing information, page 8, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=8)

Note: The first passage ends at the foot of page 7 and the sentence continues on page 8 in the second passage.

<a id="qulipta-kidney-disease"></a>

### What is the Qulipta dose for kidney disease or dialysis?

> “The renal route of elimination plays a minor role in the clearance of atogepant [see Clinical 
> Pharmacology (12.3)]. For episodic migraine, in patients with severe renal impairment 
> (CLcr 15-29 mL/min) and in patients with end-stage renal disease (ESRD) (CLcr <15 mL/min), 
> the recommended dosage of QULIPTA is 10 mg once daily; in patients with ESRD undergoing 
> intermittent dialysis, QULIPTA should preferably be taken after dialysis [see Dosage and 
> Administration (2.2)]. For chronic migraine, use of QULIPTA in patients with severe renal 
> impairment and in patients with ESRD is not recommended. No dose adjustment is 
> recommended for patients with mild or moderate renal impairment.”

Source: [QULIPTA: Prescribing information, page 8, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=8)

<a id="qulipta-liver-disease"></a>

### Can Qulipta be used with liver disease (hepatic impairment)?

> “No dose adjustment of QULIPTA is recommended for patients with mild or moderate hepatic 
> impairment. Avoid use of QULIPTA in patients with severe hepatic impairment [see Adverse 
> Reactions (6.1) and Clinical Pharmacology (12.3)].”

Source: [QULIPTA: Prescribing information, page 8, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=8)

> “In patients with pre-existing mild (Child-Pugh Class A), moderate (Child-Pugh Class B), or 
> severe (Child-Pugh Class C) hepatic impairment, the total atogepant exposure was increased by 
> 24%, 15%, and 38%, respectively. Due to a potential for liver injury in patients with severe 
> hepatic impairment, avoid use of QULIPTA in patients with severe hepatic impairment [see Use 
> in Specific Populations (8.7)].”

Source: [QULIPTA: Prescribing information, page 10, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=10)

## Related pages
- [Medical information: Qulipta (atogepant): Preventive treatment of migraine](https://www.evicenter.com/medical-information/qulipta--preventive-treatment-of-migraine)
- [Indication](https://www.evicenter.com/medical-information/qulipta--preventive-treatment-of-migraine/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/qulipta--preventive-treatment-of-migraine/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/qulipta--preventive-treatment-of-migraine/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/qulipta--preventive-treatment-of-migraine/safety)
- [Drug interactions](https://www.evicenter.com/medical-information/qulipta--preventive-treatment-of-migraine/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/qulipta--preventive-treatment-of-migraine/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/qulipta--preventive-treatment-of-migraine/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/qulipta--preventive-treatment-of-migraine/access-and-coverage)
